
To assess the safety, zzso and use of continuous zzso infusion zzso of zzso for cancer pain, we reviewed the clinical experience of 36 patients who received 46 zzso zzso was always preceded by a period of repetitive dosing of zzso zzso was used in 36 zzso zzso in four, zzso in four, zzso in one, and zzso in zzso Mean doses during zzso were the zzso equivalent of 17 zzso zzso zzso at the start, 69 zzso zzso zzso at the zzso and 52 zzso zzso zzso at zzso zzso relief was acceptable during 28 zzso unacceptable during 17, and unknown during zzso There were few toxic effects other than zzso Twenty-five patients died, 12 resumed zzso or oral zzso six continued zzso with a different zzso zzso analgesia in zzso and outcome was zzso in zzso This review suggests that zzso zzso is safe, zzso analgesia may require rapid escalation of infusion rates, zzso patient response varies and lack of acceptable analgesia may occur in up to zzso zzso ineffective zzso with one drug may be followed by success with another, zzso zzso should be preceded by a period of repetitive zzso zzso with the same drug, and zzso guidelines can be developed which incorporate zzso zzso 

